Tuberculosis Treatment Outcomes of Patients with Diabetes Mellitus. 2022

Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

BACKGROUND Diabetes mellitus (DM) is one of the risk factors for progression from latent to active tuberculosis. However, the effect of DM on subsequent tuberculosis treatment is still inconclusive. OBJECTIVE To compare tuberculosis treatment outcomes and the rate of drug resistance of tuberculosis patients with or without DM. METHODS This case-control study was conducted between 2005 and 2015 at the only tuberculosis ward in Israel. All 80 tuberculosis patients who had DM and were hospitalized during the study period were included in this study, as were a randomized sample of 213 tuberculosis patients without DM. Demographic, clinical, and laboratory data were collected from patient files in the hospital and clinics after discharge. RESULTS Tuberculosis patients with DM were more often older and more likely to be Israeli citizens with a lower socioeconomic status than patients without DM. No statistically significant differences were found in clinical presentation, radiological findings, and sputum smear tests between the two groups. Culture converting times were prolonged in patients with DM compared to normoglycemic patients. Multidrug drug resistance tuberculosis was more common among normoglycemic tuberculosis patients than tuberculosis patients with DM (9.2% vs. 1.6%, P = 0.12). Treatment success rates were 76.2% and 83.1% for tuberculosis patients with or without DM, respectively (P = 0.18). DM was not statistically significant in the multivariate analysis predicting treatment success, which controlled for age, citizenship, compliance, addictions, and chronic diseases. CONCLUSIONS The presence of DM does not necessarily affect tuberculosis treatment outcomes as long as treatment compliance is optimal.

UI MeSH Term Description Entries
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014376 Tuberculosis Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS. Koch's Disease,Kochs Disease,Mycobacterium tuberculosis Infection,Infection, Mycobacterium tuberculosis,Infections, Mycobacterium tuberculosis,Koch Disease,Mycobacterium tuberculosis Infections,Tuberculoses
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016896 Treatment Outcome Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series. Rehabilitation Outcome,Treatment Effectiveness,Clinical Effectiveness,Clinical Efficacy,Patient-Relevant Outcome,Treatment Efficacy,Effectiveness, Clinical,Effectiveness, Treatment,Efficacy, Clinical,Efficacy, Treatment,Outcome, Patient-Relevant,Outcome, Rehabilitation,Outcome, Treatment,Outcomes, Patient-Relevant,Patient Relevant Outcome,Patient-Relevant Outcomes
D018088 Tuberculosis, Multidrug-Resistant Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. Tuberculosis, Drug-Resistant,Tuberculosis, MDR,Tuberculosis, Multi-Drug Resistant,Drug-Resistant Tuberculosis,MDR Tuberculosis,Multi-Drug Resistant Tuberculosis,Multidrug-Resistant Tuberculosis,Tuberculosis, Drug Resistant,Tuberculosis, Multi Drug Resistant,Tuberculosis, Multidrug Resistant

Related Publications

Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
April 2009, The American journal of tropical medicine and hygiene,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
August 2020, Iranian journal of public health,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
April 2021, Open forum infectious diseases,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
January 1997, Problemy tuberkuleza,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
January 2002, Problemy tuberkuleza,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
April 2013, The American journal of the medical sciences,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
July 2014, Lung India : official organ of Indian Chest Society,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
January 1988, Problemy tuberkuleza,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
January 1962, Problemy tuberkuleza,
Ido Tzanani, and Daniel Bendayan, and Anat Jaffe, and Zohar Mor
January 1987, Problemy tuberkuleza,
Copied contents to your clipboard!